CCO Interactive Case Challenges

Use of Resistance Testing to Guide Therapy in HIV-Infected Patients with Multiple Regimen Failure

Interactive Case Challenges

Management of a Patient After First and Second Regimen Failure

Program Director:
John P. Phair, MD

Faculty:

Joel E. Gallant, MD, MPH headshot
  • Joel E. Gallant, MD, MPH

CME CREDIT INFORMATION

Release Date: 09/06/05

Expiration Date: 09/05/06


Physicians: maximum of 0.5 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Joel E. Gallant, MD, MPH, explores the use of resistance testing to guide treatment decisions in a patient who presents with virologic failure on an initial NNRTI-based regimen.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss advantages and disadvantages to the use of genotype vs phenotype vs combined resistance testing

  • Describe treatment strategies for the management of patients with multiple thymidine analogue and protease inhibitor mutations

  • Outline what is known about the selection and impact of the I50L and K103N mutations

Use and Interpretation of Resistance Tests in a Highly Treatment-Experienced Patient

CME Program Director:
John P. Phair, MD

Faculty:

Eric S. Daar, MD headshot
  • Eric S. Daar, MD

CME CREDIT INFORMATION

Release Date: 12/14/05

Expiration Date: 12/13/06


Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Eric S. Daar, MD, uses this case of a highly treatment-experienced patient to discuss the advantages and disadvantages and proper interpretation of genotype and phenotype testing.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Review current guidelines on the appropriate settings to use resistance testing.
  • Discuss advantages and disadvantages of the use of genotype vs phenotype vs combined resistance testing.
  • Describe the challenges of interpreting resistance testing data and identifying and interpreting discordance.

Management of a Patient With NNRTI Hypersusceptibility in the Setting of High-Level NRTI and PI Resistance

CME Program Director:
John P. Phair, MD

Faculty:

Andrew R. Zolopa, MD headshot
  • Andrew R. Zolopa, MD

CME CREDIT INFORMATION

Release Date: 01/09/06

Expiration Date: 01/08/07


Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Andrew R. Zolopa, MD, discusses management decisions in a highly NRTI- and PI-experienced patient with low-level viremia, a stable CD4+ cell count, and complaints of ongoing tolerability and physical appearance issues.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Review how to interpret resistance test results in the presence of hypersusceptibility and partial drug susceptibility.
  • Describe considerations when using tenofovir and didanosine in an antiretroviral regimen.
  • Discuss the clinical relevance of NNRTI hypersusceptibility and the extent to which it should affect management decisions.
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.